title: Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
abstract: A total of 42 patients with hormone-refractory prostate cancer received E-E therapy. Oral estramustine phosphate (EMP) was administered twice daily for a total daily dose of 560 mg every day and oral etoposide (E-E therapy, 50 mg/body/day) was given on days 1-21 and stopped on days 22-35. Treatment was continued until the disease progression was confirmed radiographically or PSA had increased from base line of at least 25%. The median follow-up period after E-E therapy was 77.4 months (range : 12.5 to 122.3). Nineteen patients (43%) achieved a PSA decrease of 50% or greater. The median survival time of the patients who had a decrease of 50% or greater in the PSA value (PSA responder) was 29.3 months and the patients who did not (PSA non-responder) was 14.1 months (p = 0.01). There were no significant differences between PSA responders and non-responders when taking into account variables. Excluding those patients with only PSA elevation, the survival time was 14.9 months with no significant difference between PSA responders and non-responders. The toxicities (grade 3 or more) were identified as anemia, leukocytopenia thrombocytopenia, cardiovascular events, and gastrointestinal and hepatic disorders, which occurred in 0, 5, 2, 2, 14, and 2% of the patients, respectively. E-E therapy was considered to be an active oral regimen and well-tolerated for outpatients with hormone-refractory prostate cancer in Japanese patients.
authors.affiliation: The Department of Urology, Shikoku Cancer Center.
authors.forename: Kousaku
authors.initials: K
authors.lastname: Numata
authors.forename: Noriyoshi
authors.initials: N
authors.lastname: Miura
authors.forename: Koji
authors.initials: K
authors.lastname: Azuma
authors.forename: Takashi
authors.initials: T
authors.lastname: Karashima
authors.forename: Kotaro
authors.initials: K
authors.lastname: Kasahara
authors.forename: Hironori
authors.initials: H
authors.lastname: Nakatsuzi
authors.forename: Katsuyoshi
authors.initials: K
authors.lastname: Hashine
authors.forename: Yoshiteru
authors.initials: Y
authors.lastname: Sumiyoshi
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004961:Estramustine / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D004961:Estramustine; D005047:Etoposide; D017430:Prostate-Specific Antigen